Drug intelligence / Profile preview

68Ga-BMV101

Development stage: Phase 1
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

68Ga-BMV101 is a cysteine-cathepsin-targeted dual optical/PET probe used for monitoring inflammatory macrophages in fibrotic disease. It was developed for non-invasive imaging of idiopathic pulmonary fibrosis (IPF) and has been studied in both preclinical models and human clinical trials. The probe uses gallium-68 as its radionuclide, which has a short half-life of 68 minutes, requiring imaging within the first few hours of administration.

Other names: [68Ga]Ga-BMV10168Ga-DOTA-BMV101

Targets

CTS (Cathepsin family)CTSB (Cathepsin B)

Beyond the preview

Go deeper on 68Ga-BMV101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 68Ga-BMV101.

Explore the full profile